Skip to content

TENAX THERAPEUTICS, INC.: 10-Q filed 2022-08-11

What TENAX THERAPEUTICS, INC. reported in its quarterly report filed 2022-08-11 (fiscal Q2 2022): 29 published measures, 81 facts as tagged in accession 0001654954-22-011073.

This filing

Form
10-Q (quarterly report)
Filed
2022-08-11
Fiscal period
fiscal Q2 2022
Accession
0001654954-22-011073 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TENAX THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-06-308,355,483USD
At 2021-12-315,992,235USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-06-301,571,681USD
At 2021-12-311,747,567USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-06-306,783,802USD
At 2022-03-311,606,201USD
At 2021-12-314,244,668USD
At 2021-06-301,471,132USD
At 2021-03-313,095,681USD
At 2020-12-314,625,562USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-06-307,229,179USD
At 2021-12-315,583,922USD
At 2021-06-301,671,422USD
At 2020-12-316,250,241USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-302,861,021USD91
2022-01-01 to 2022-06-305,582,557USD181
2021-04-01 to 2021-06-301,717,016USD91
2021-01-01 to 2021-06-3025,465,156USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-6,368,886USD181
2021-01-01 to 2021-06-30-5,066,239USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2022-01-01 to 2022-06-306,323USD181
2021-01-01 to 2021-06-301,875USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-06-308,020,466USD181
2021-01-01 to 2021-06-30544,651USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-6,323USD181
2021-01-01 to 2021-06-30-57,231USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-06-30-284,076,742USD
At 2021-12-31-278,494,185USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2022-06-3010,844USD
At 2021-12-317,108USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-302,861,892USD91
2022-01-01 to 2022-06-305,580,531USD181
2021-04-01 to 2021-06-301,964,500USD91
2021-01-01 to 2021-06-3025,714,162USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-06-308,101,542USD
At 2021-12-315,689,000USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2022-04-01 to 2022-06-301,484USD91
2022-01-01 to 2022-06-304,071USD181
2021-04-01 to 2021-06-30336USD91
2021-01-01 to 2021-06-30949USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-06-301,445,798USD
At 2021-12-311,563,978USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-06-30919,384USD
At 2021-12-31859,638USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-04-01 to 2022-06-302,861,892USD91
2022-01-01 to 2022-06-305,580,531USD181
2021-04-01 to 2021-06-301,964,500USD91
2021-01-01 to 2021-06-3025,714,162USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-04-01 to 2022-06-301,524,465USD91
2022-01-01 to 2022-06-302,702,360USD181
2021-04-01 to 2021-06-30693,222USD91
2021-01-01 to 2021-06-3023,069,424USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-06-3025,206,914shares
At 2021-12-3125,206,914shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-06-30290,858,023USD
At 2021-12-31282,736,332USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2022-06-30234,662USD
At 2021-12-31287,692USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2022-06-30239,039USD
At 2021-12-31290,781USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2022-06-308,435USD
At 2021-12-318,435USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2022-06-30434,539USD
At 2021-12-31704,340USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-2,861,021USD91
2022-01-01 to 2022-03-31-2,721,536USD90
2021-04-01 to 2021-06-30-1,717,016USD91
2021-01-01 to 2021-03-31-23,748,140USD90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2022-04-01 to 2022-06-302,861,021USD91
2022-01-01 to 2022-06-305,582,557USD181
2021-04-01 to 2021-06-301,716,888USD91
2021-01-01 to 2021-06-3025,465,360USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-301,337,427USD91
2022-01-01 to 2022-06-302,878,171USD181
2021-04-01 to 2021-06-301,271,278USD91
2021-01-01 to 2021-06-302,644,738USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2022-04-01 to 2022-06-301,200USD91
2022-01-01 to 2022-06-302,600USD181
2021-04-01 to 2021-06-301,000USD91
2021-01-01 to 2021-06-302,000USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2022-01-01 to 2022-06-30396USD181

Inspect the source

Entity
TENAX THERAPEUTICS, INC. / CIK 0000034956
Captured
2026-09-19T14:46:45.117Z
SEC response SHA-256
3f4f90f5f823d316ffb20bc63506ae090888657f5ff1cb9568439e153f028cf5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000034956.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))